Ibandronate Sodium Monohydrate is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase). It works by blocking the mevalonate pathway, which inhibits the modification of small GTPases, leading to tumor cell apoptosis and reduced bone resorption. This compound also inhibits tumor cell proliferation, promotes FAS gene expression, and can provide synergistic anti-tumor effects when combined with anti-estrogen compounds. It is commonly used in research related to osteoporosis and bone metastatic tumors, including breast cancer bone metastasis.
- Orally active and selective FPP synthase inhibitor
- Blocks mevalonate pathway
- Induces tumor cell apoptosis
- Inhibits bone resorption
- Inhibits tumor cell proliferation
- Promotes expression of pro-apoptotic gene FAS
- Useful for osteoporosis and bone metastatic tumor research